Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joost DeJongh

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2021
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapyJoost DeJongh, Maurice Ahsman, Nelleke Snelder
Journal of Clinical Pharmacology|November 12, 2013
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazarFrances Stringer, Joost DeJongh, Graham Scott, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 17, 2013
Pharmacokinetics of recombinant human antithrombin in delivery and surgery patients with hereditary antithrombin deficiencyJoost DeJongh, Johan Frieling, Simon Lowry, et al.
Pharmaceutical Research|July 20, 2005
Disease system analysis: basic disease progression models in degenerative diseaseTeun M Post, Jan I Freijer, Joost DeJongh, et al.
Diabetes Technology & Therapeutics|December 23, 2014
Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetesFrances Stringer, Joost DeJongh, Kazuaki Enya, et al.
Bulletin of Mathematical Biology|October 7, 2006
Application of the convection-dispersion equation to modelling oral drug absorptionJan I Freijer, Teun M Post, Bart A Ploeger, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model developmentMartijn van Noort, Martijn Ruppert, Joost DeJongh, et al.
Journal of Clinical Pharmacology|February 28, 2013
Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazarFrances Stringer, Bart A Ploeger, Joost DeJongh, et al.
Biopharmaceutics & Drug Disposition|June 21, 2020
Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft modelAkifumi Kogame, Kaori Ishikawa, Joost DeJongh, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 17, 2025
Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic-pharmacodynamic modelJoost DeJongh, Elaine Cadogan, Michael Davies, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2021
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapyJoost DeJongh, Maurice Ahsman, Nelleke Snelder
Journal of Clinical Pharmacology|November 12, 2013
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazarFrances Stringer, Joost DeJongh, Graham Scott, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 17, 2013
Pharmacokinetics of recombinant human antithrombin in delivery and surgery patients with hereditary antithrombin deficiencyJoost DeJongh, Johan Frieling, Simon Lowry, et al.
Pharmaceutical Research|July 20, 2005
Disease system analysis: basic disease progression models in degenerative diseaseTeun M Post, Jan I Freijer, Joost DeJongh, et al.
Diabetes Technology & Therapeutics|December 23, 2014
Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetesFrances Stringer, Joost DeJongh, Kazuaki Enya, et al.
Bulletin of Mathematical Biology|October 7, 2006
Application of the convection-dispersion equation to modelling oral drug absorptionJan I Freijer, Teun M Post, Bart A Ploeger, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 8, 2024
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model developmentMartijn van Noort, Martijn Ruppert, Joost DeJongh, et al.
Journal of Clinical Pharmacology|February 28, 2013
Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazarFrances Stringer, Bart A Ploeger, Joost DeJongh, et al.
Biopharmaceutics & Drug Disposition|June 21, 2020
Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft modelAkifumi Kogame, Kaori Ishikawa, Joost DeJongh, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 17, 2025
Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic-pharmacodynamic modelJoost DeJongh, Elaine Cadogan, Michael Davies, et al.
Pageof 3